GSK: ‘Armageddon’ Claims Overstated For Skinny-Label Generics
Originator Pushes Back Against Teva Petition For Federal Circuit ‘En Banc’ Rehearing
In a brief opposing Teva’s call for a US appeals court to rehear controversial litigation over carved-out indications and induced infringement, GSK has insisted that previous decisions in its favor do not amount to doomsday for skinny-label generics.
